原发性免疫性血小板减少症诊疗国际共识报告更新版
本文是2010年国际共识报告的更新版,通过批判性综述检索2009至2018年发表的文献,由专家小组筛选、评价并分级研究后制定更新共识推荐。最终文件提供成人和儿童ITP及妊娠期ITP的诊断与管理共识推荐,并纳入生活质量考量。
要点
- 更新了成人和儿童ITP及妊娠期ITP的诊断与管理共识推荐。
- 纳入生活质量考量作为ITP管理的一部分。
- 基于2009至2018年文献的系统评价与专家分级制定推荐。
核心结论
- 提供了基于2009至2018年新数据的ITP诊断与管理更新共识推荐。
研究设计与样本
- 对2009至2018年发表的文献进行批判性综述,由专家小组筛选、评价并分级研究后制定共识推荐。
临床怎么用
- 共识推荐覆盖成人、儿童及妊娠期ITP的诊断与管理,并纳入生活质量考量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Over the last decade, there have been numerous developments and changes in treatment practices for the management of patients with immune thrombocytopenia (ITP). This article is an update of the International Consensus Report published in 2010. A critical review was performed to identify all relevant articles published between 2009 and 2018. An expert panel screened, reviewed, and graded the studies and formulated the updated consensus recommendations based on the new data. The final document provides consensus recommendations on the diagnosis and management of ITP in adults, during pregnancy, and in children, as well as quality-of-life considerations.
引用
- Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019. PMID: 31770441. doi:10.1182/bloodadvances.2019000812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。